SCHEMBL14722724

SCHEMBL14722724

COc1nn(C2CCCCO2)c2cccc(C#N)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
EGFR P00533 1/20 0.34
BTK Q06187 1/20 0.34
GRM2 Q14416 1/20 0.34
CYP4F2 P78329 3/20 0.34
CYP4A11 Q02928 3/20 0.34
DPP4 P27487 3/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
ATR Q13535 2/20 0.33
CYP3A4 P08684 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
SLC6A4 P31645 1/20 0.33
PLK1 P53350 1/20 0.33
PDE1A P54750 1/20 0.32
PDE1B Q01064 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14722738 0.85 GAA (0.40) RETALDH1A1NPSR1GRM2CYP4F2
SCHEMBL23331750 0.83 EGFR (0.34) RETEGFRBTKCYP4F2CYP4A11
SCHEMBL14723110 0.83 EGFR (0.35) RETALDH1A1EGFRBTKCYP4F2
SCHEMBL14723265 0.82 RET (0.36) RETALDH1A1NPSR1GRM2CYP4F2
SCHEMBL30540754 0.74 EGFR (0.37) RETEGFRBTKGRM2CYP4F2
SCHEMBL15278356 0.73 KRAS (0.33) RETCYP4F2CYP4A11RXRARXRB
SCHEMBL14722997 0.72 RXRA (0.41) RETALDH1A1NPSR1GRM2CYP4F2
SCHEMBL30950290 0.72 CYP4F2 (0.41) RETCYP4F2CYP4A11RXRARXRB
SCHEMBL5616694 0.71 RET (0.38) RETCYP4F2CYP4A11RXRARXRB
SCHEMBL22777080 0.71 PDE10A (0.38) RETEGFRBTKCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2748159-A1 SERINE/THREONINE PAK1 INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-07-02 EP disclosed
US-8637537-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2014-01-28 US disclosed
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2013-08-29 US disclosed
WO-2013026914-A1 SERINE/THREONINE PAK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225620-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 RET 97/4885ALDH1A1 2874/4885NPSR1 3265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.